Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James M G Larkin

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
The Oncologist|November 6, 2010
Fatigue in renal cell carcinoma: the hidden burden of current targeted therapiesJames M G Larkin, Lynda M Pyle, Martin E Gore
Neuro-Oncology|June 10, 2008
What is the risk of intracranial bleeding during anti-VEGF therapy?Craig P Carden, James M G Larkin, Mark A Rosenthal
Future Oncology (London, England)|November 27, 2015
Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directionsCamillo Porta, Giampaolo Tortora, James M G Larkin, et al.
Annals of Diagnostic Pathology|June 21, 2011
Metastatic renal mucinous tubular and spindle cell carcinoma. Atypical behavior of a rare, morphologically bland tumorKhin Thway, John du Parcq, James M G Larkin, et al.
Therapeutic Advances in Medical Oncology|July 27, 2011
Systemic therapy for advanced renal cell carcinomaJames M G Larkin, Emma L S Kipps, Ceri J Powell, et al.
Applied Health Economics and Health Policy|August 27, 2025
Structured Expert Elicitation to Inform Long-Term Survival Extrapolations in Advanced Renal Cell CarcinomaDawn Lee, Zain Ahmad, James M G Larkin, et al.
Immunology|January 16, 2010
The melanocortin receptor agonist NDP-MSH impairs the allostimulatory function of dendritic cellsLa'Verne P Rennalls, Thomas Seidl, James M G Larkin, et al.
Melanoma Research|March 29, 2006
Anti-alphaGal-dependent complement-mediated cytotoxicity in metastatic melanomaJames M G Larkin, Peter J Norsworthy, Roger P A'Hern, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2002
Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidenceDesiree F Kolomainen, James M G Larkin, Mohammad Badran, et al.
The Lancet. Oncology|August 8, 2016
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trialBrian I Rini, Tanya B Dorff, Paul Elson, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
The Oncologist|November 6, 2010
Fatigue in renal cell carcinoma: the hidden burden of current targeted therapiesJames M G Larkin, Lynda M Pyle, Martin E Gore
Neuro-Oncology|June 10, 2008
What is the risk of intracranial bleeding during anti-VEGF therapy?Craig P Carden, James M G Larkin, Mark A Rosenthal
Future Oncology (London, England)|November 27, 2015
Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directionsCamillo Porta, Giampaolo Tortora, James M G Larkin, et al.
Annals of Diagnostic Pathology|June 21, 2011
Metastatic renal mucinous tubular and spindle cell carcinoma. Atypical behavior of a rare, morphologically bland tumorKhin Thway, John du Parcq, James M G Larkin, et al.
Therapeutic Advances in Medical Oncology|July 27, 2011
Systemic therapy for advanced renal cell carcinomaJames M G Larkin, Emma L S Kipps, Ceri J Powell, et al.
Applied Health Economics and Health Policy|August 27, 2025
Structured Expert Elicitation to Inform Long-Term Survival Extrapolations in Advanced Renal Cell CarcinomaDawn Lee, Zain Ahmad, James M G Larkin, et al.
Immunology|January 16, 2010
The melanocortin receptor agonist NDP-MSH impairs the allostimulatory function of dendritic cellsLa'Verne P Rennalls, Thomas Seidl, James M G Larkin, et al.
Melanoma Research|March 29, 2006
Anti-alphaGal-dependent complement-mediated cytotoxicity in metastatic melanomaJames M G Larkin, Peter J Norsworthy, Roger P A'Hern, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2002
Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidenceDesiree F Kolomainen, James M G Larkin, Mohammad Badran, et al.
The Lancet. Oncology|August 8, 2016
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trialBrian I Rini, Tanya B Dorff, Paul Elson, et al.
Pageof 3